Open access
Aug 2026
Body Mass Index and Outcomes after CD19 Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory B-Cell Lymphoma: A Nationwide Registry Study.
Pretreatment BMI may serve as a simple clinical marker associated with early outcomes after CAR T-cell therapy, although this association may be partly explained by disease status at infusion or unmeasured disease burden.
Tatsuya Konishi, W. Kitamura, Shohei Mizuno et al.
· Transplantation and Cellular... · 0 citations